Galapagos discovers and develops small molecule medicines with novel modes of action, several of which show promising patient ... results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and available to patients in Europe, Great Britain and Japan (under a collaboration with Gilead) for rheumatoid arthritis. Our aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need. Galapagos has more than 1,200 employees worldwide, with sites in Belgium (international headquarters), the Netherlands, France, Germany, Italy, Spain, Switzerland, the UK and the US. read more